- ستاد توسعه زیستفنّاوری کشور (اردیبهشت 1394) برنامه عملیاتی کارگروه واکسن، تهران.
- سرلک، محمدعلی؛ ویسه، سیدمهدی؛ پوراشرف، یاسان ا... و مهدیزاده، حسین (1391) طراحی مدل سازمان معنویتگرا در آموزش عالی ایران، پژوهشهایمدیریتعمومی، (18)، 24-5.
- کریمی، صدیقه؛ نصر، احمدرضا (1392)، روش‌های تجزیه‌وتحلیل دادههای مصاحبه، عیار پژوهش در علوم انسانی، (7)، 94-71.
- قدسی، محمد (1350) تاریخچه خدمات 50 ساله انستیتو پاستور ایران، تهران، انتشارات انستیتو پاستور.
- مرندی، وحید (1382) شناسایی مزیت‌های نسبی و فرصت‌های سرمایه‌گذاری در کشور، شالوده رویکرد موثّر به تحقیق و توسعه، چهارمین همایش بین‌المللی مراکز تحقیق و توسعه: جامعه مراکز تحقیق و توسعه صنایع و معادن- وزارتهای علوم، تحقیقات و فن‌آوری، صنایع و معادن.
- مرندی، وحید (1380) توسعه صنعتی زیستفنّاوری در کشور، اهمیت و راهکارها، دومین همایش ملی بیوتکنولوژی: وزارت علوم، تحقیقات و فنّاوری- مرکز ملی تحقیقات مهندسی ژنتیک و تکنولوژی زیستی.
- مرندی، وحید (1383) مورد کاوی تحقّق اهداف و تحلیل رویکردهای مدیریت در یک پروژه عمرانی ملّی، دومین کنفرانس بین‌المللی مدیریت: دانشگاه صنعتی شریف- سازمان گسترش و نوسازی صنایع ایران- گروه پژوهشی صنعتی آریانا.
- مرندی، وحید (1384) تحلیل مؤلفه مدیریت دانایی در یک پروژه راهبردی ملّی، پنجمین همایش بین‌المللی مراکز تحقیق و توسعه: جامعه مراکز تحقیق و توسعه صنایع و معادن- وزارت علوم، تحقیقات و فن‌آوری- وزارت صنایع و معادن.
- Amit, R. and Zott, C. (2001) ‘Value creation in e-business’, Strategic Management Journal, Vol. 22, No. 6, pp.493–520.
- Bernstein, B. Singh.P.J. (2006) an integrated innovation process model based on practices of Australian biotechnology firms, Technovation, 26, pp.561–572.
- Chaturvedi, K. and Chataway, J. (2012) Strategic integration of knowledge in Indian pharmaceutical firms: creating competencies for innovation, Int. J. Business Innovation and Research, Vol. 1, No. 1–2, pp.27–50.
- Clemens. J.D. Jodar.L (2004) Translational research to assist policy decisions about introducing new vaccines in developing countries, J Health Popul Nutr 2004; 22:223:31 pmid: 15609774
- Folkers.G.K, Fauci.A.S, (2003) Vaccine Research and Development: The Key Roles of the National Institutes of Health and Other United States Government Agencies, The Jordan Report, NIH Publications, USA.
- Garnier, J.P (2008), Rebuilding the R&D machine in big pharma, Harvard Business Review, May Vol. 86, No. 5,pp.68–76.
- Haeussler, C. (2007) Proactive versus reactive m&a activities in the biotechnology industry, Journal of High Technology Management Research, Vol. 17, No. 2, pp.109–123.
- Hardman Reis.T (2006) the role of intellectual property in the global challenge for immunization.
J World Intellect Prop, 9 (4): 413–25.
Doi:
10.1111/j.1422-2213.2006.00284.x.
- Innovation in Pharmaceutical Biotechnology: Comparing national innovation systems at the sectoral level (2006) OECD, ISBN-92-64-01403-9.
- International Monetary Fund Report (2014) IMF Survey: More efficient public investment Mideast, Central Asia priority, The International Monetary Fund (IMF).
- KFDA (2012) recent trends and Korea’s cases in the development of gene therapy products KFDA. 2008; Available from:
- Keen, P. Qureshi, S. (2006) Organizational transformation through business models: a framework for business model design, Paper presented in the Proceedings of the 39th Hawaii International Conference on System Sciences, pp.1–10.
- Kellogg, J.L. (2002) Managing R&D in the biotechnology Sector, Kellogg Graduate School of Management, Working Paper, pp.1–20.
- Kurdin.A (2012) Business models and opportunities for cancer vaccine developers, Landes Bioscience: Human vaccine & Immunotherapeutics, Oct. 2012, 8; 10, 1431-1438.
- Kleinbaum, A. Tushman, M (2007) Building bridges: the social structure of interdependent innovation, Strategic Entrepreneurship Journal, Vol. 1, No. 1–2, pp.103–122.
- Malone.K.M, Hinman.A.R, (2007) Vaccination mandates: The public health imperative & individual rights, Oxford University Press, New York, 262-284.
- Matherne, B.P. (2007) Does whom you know matter in venture capital networks? The AcademyofManagement Perspectives, Vol. 21, No. 4, pp.85–86.
- McDonough, III, E.F. Athanassiou, N. Barczak, G. (2006) Networking for global new product innovation, Int. J. Business Innovation and Research, Vol. 2, No. 1–2, pp.9–26.
- McGrath, R. Nerkar, A. (2004) Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms, Strategic Management Journal, Vol. 25, No. 1, pp.1–21.
- Nerkar, A.Roberts, P. (2004) Technological and product-market experience and the success of new product introductions in the pharmaceutical industry, Strategic Management Journal, Vol. 25, No. 8, pp.779–799.
- Newall, A.T. Reyes, J.F. Wood, J.G. McIntyre, P. Menzies, R. Beutels, P. (2013)
Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. February 2014, Vaccine 32 (7): 759–765.
Doi:
10.1016/j.vaccine.2013.11.067.
- Oyston.P, Robinson.K, The current challenges for vaccine development (2012) Journal of Medical Microbiology, 61, 889-894.
- Qian, G, Wang, D (2000) Factors that affect performance of US small and medium sized technology-based enterprises: does multinationality matter? J of Business andEntrepreneurship, Vol.11, No.4, pp.119–131.
- Qian, G, Li, L. (2003) Profitability of small- and medium-sized enterprises in high-tech industries: the case of the biotechnology industry, Strategic Management Journal, Vol. 24, No. 9, pp.881–887.
- Rathore. A. S, Bhalghat. M, Patra. A.K (2012) Key Considerations for Development and production of vaccine product, Biopharm. Int. J. s1_s6.
- Rhyne.L.C (2009) Business model design for biotechnology firms, International Journal of Business Innovation and Research, Vol. 3, No. 3, pp.298-310.
- Rice, M. O’Conner, S. and Pierantozyi, R. (2008) Implementing a learning plan to counter project uncertainty, Sloan Management Review, Vol. 49, No. 2, pp.54–62.
- Rothaermel, F, Deeds, D. (2004) Exploration and exploitation alliances in biotechnology: a system of new product development, Strategic Management Journal, Vol. 25, No. 3, pp.201–221.
- Rottingen.J.A, Regmi.S, Eide.M, (2013) Mapping of available health research and development data: what’s there, what’s missing, and what role is there for a global observatory? Health Policy, The Lancet Journal, Oct.12, 2013, Vol. 382, 1286-1307.
- Seelos, C, Mair, J (2007) Profitable business models and market creation in the context of deep poverty: a strategic view, Academy of Management Perspectives, Vol. 21, No. 4, pp.49–63.
- Stam, W. Elfring, T (2008) Entrepreneurial orientation and new venture performance: the moderating role of intra- and extra-industry social capital, Academy of Management Journal, Vol. 51, No. 1, pp.97–111.
- Teece, D (1982) Toward an economic theory of the multiproduct firm, Journal of EconomicBehavior and Organization, Vol. 3, No. 1, pp.39–63.
- Thomas, L (2004) Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industry, Strategic Management Journal,Vol. 25, No. 9, pp.865–886.
- Thompson, K. M. Tebbens, R. J. Pallansch, M. A. Kew, O. M.Sutter, R. W. Aylward, R. B. et al. (2008) The risks, costs, and benefits of possiblefuture global policies formanaging polioviruses. Am J Public Health, 98, 1322–1330.
- Tolstoy, D. Agndal, H. (2008) Network resource combinations in new international ventures, Paper presented in the Proceedings of the Global Business Innovation and DevelopmentConference, Rio de Janeiro, Brazil, pp.453–454.
- Voss, G. Sirdeshmukh, D. Voss, Z. (2008) The effects of slack resources and environmental threat on product exploration and exploitation, Academy of Management Journal, Vol. 51, No. 1, pp.147–164.
-
Wasserman.E, (2016)
Astellas cancer med Xtandi draws fire as U.S. lawmakers demand a pricing hearing, Fierce Pharma, Regulatory Notes, 29 March 2016, USA.
- Wells, R.M.J. (2008) the product innovation process: are managing information flows and cross-functional collaboration key? The Academy of Management Perspectives, Vol. 22, No. 1, pp.58–59.
- Widdus. R. (2010) Vaccine Innovation done differently, Bulletin of the W.H.O 2010; 88: 880-880. Doi: 10.247/BLT.10.082826
- Woiceshyn, J. Folkenberg, L (2008) Value creation in knowledge-based firms: aligning problems and resources, Academy of Management Perspectives, Vol. 22, No. 2, and pp.85–99.
- World Bank. (2006) Korea as a Knowledge Economy:Evolutionary Process and Lessons Learned. The World Bank, Washington D.C. 2-15.
- World Bank. (2017) Doing Business: 2018, the World Bank, Oct. 2017, Washington D.C. 2-15.
- Zhao, R. (2003) Transition in R&D management control system: case study of a biotechnology research institute in china, Journal of High Technology Management Research, Vol. 14, No. 2, pp.213–229.
)